Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of aripiprazole lauroxil in stable schizophrenia
2012-003996-20Phase 3Completed
- Sponsor
- Alkermes
- Start
- Nov 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aripiprazole lauroxil in schizophrenia, sponsored by Alkermes. Primary endpoint: Long-term safety. Started Nov 2012; status: completed.
02
Drugs
aripiprazole lauroxil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2012-003996-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003996-20.